NCT06728553View on ClinicalTrials.gov

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

June 27, 2025

Study Completion Date

July 28, 2025

Conditions
Migraine
Interventions
DRUG

MTX101

One 2 mg sublingual tablet of MTX101

DRUG

Placebo

One sublingual tablet of placebo

Trial Locations (7)

32504

Synergy Clinical Research/Emerald Coast Center for Neurological Disorders, Pensacola

33176

Brainstorm Research, Miami

48334

QUEST Research Institute, Farmington Hills

70115

DelRicht Research, New Orleans

84107

Wasatch Clinical Research, Salt Lake City

90048

Clinical Research Institute, LLC, Santa Monica

92037

Kaizen Brain Center, La Jolla

Sponsors
All Listed Sponsors
lead

Manistee Therapeutics

INDUSTRY

NCT06728553 - Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults | Biotech Hunter | Biotech Hunter